BACKGROUND: Levels of cannabinoid 1 receptor (CB1R) messenger RNA (mRNA) and protein, which are expressed most heavily in the cholecystokinin class of γ-aminobutyric acid (GABA) neurons, are lower in the dorsolateral prefrontal cortex in schizophrenia, and the magnitude of these differences is strongly correlated with that for glutamic acid decarboxylase 67 (GAD(67)) mRNA, a synthesizing enzyme for GABA. However, whether this correlation reflects a cause-effect relationship is unknown. METHODS: Using quantitative in situ hybridization, we measured CB1R, GAD(67), and diacylglycerol lipase alpha (the synthesizing enzyme for the endocannabinoid 2-arachidonoylglycerol) mRNA levels in the medial prefrontal cortex of genetically engineered GAD(67) heterozygous (GAD(67)(+/-)), CB1R heterozygous (CB1R(+/-)), CB1R knockout (CB1R(-/-)), and matched wild-type mice. RESULTS: In GAD(67)(+/-) mice, GAD(67) and CB1R mRNA levels were significantly reduced by 37% and 16%, respectively, relative to wild-type mice and were significantly correlated across animals (r = .61; p = .01). In contrast, GAD(67) mRNA levels were unaltered in CB1R(+/-) andCB1R(-/-) mice. Expression of diacylglycerol lipase alpha mRNA, which is not altered in schizophrenia, was also not altered in any of the genetically engineered mice. CONCLUSIONS: The findings that reduced GAD(67) mRNA expression can induce lower CB1R mRNA expression support the hypothesis that lower cortical levels of CB1Rs in schizophrenia may partially compensate for deficient GAD(67)-mediated GABA synthesis by reducing endogenous cannabinoid suppression of GABA release.
BACKGROUND: Levels of cannabinoid 1 receptor (CB1R) messenger RNA (mRNA) and protein, which are expressed most heavily in the cholecystokinin class of γ-aminobutyric acid (GABA) neurons, are lower in the dorsolateral prefrontal cortex in schizophrenia, and the magnitude of these differences is strongly correlated with that for glutamic acid decarboxylase 67 (GAD(67)) mRNA, a synthesizing enzyme for GABA. However, whether this correlation reflects a cause-effect relationship is unknown. METHODS: Using quantitative in situ hybridization, we measured CB1R, GAD(67), and diacylglycerol lipase alpha (the synthesizing enzyme for the endocannabinoid 2-arachidonoylglycerol) mRNA levels in the medial prefrontal cortex of genetically engineered GAD(67) heterozygous (GAD(67)(+/-)), CB1R heterozygous (CB1R(+/-)), CB1R knockout (CB1R(-/-)), and matched wild-type mice. RESULTS: In GAD(67)(+/-) mice, GAD(67) and CB1R mRNA levels were significantly reduced by 37% and 16%, respectively, relative to wild-type mice and were significantly correlated across animals (r = .61; p = .01). In contrast, GAD(67) mRNA levels were unaltered in CB1R(+/-) andCB1R(-/-) mice. Expression of diacylglycerol lipase alpha mRNA, which is not altered in schizophrenia, was also not altered in any of the genetically engineered mice. CONCLUSIONS: The findings that reduced GAD(67) mRNA expression can induce lower CB1R mRNA expression support the hypothesis that lower cortical levels of CB1Rs in schizophrenia may partially compensate for deficient GAD(67)-mediated GABA synthesis by reducing endogenous cannabinoid suppression of GABA release.
Authors: H Asada; Y Kawamura; K Maruyama; H Kume; R G Ding; N Kanbara; H Kuzume; M Sanbo; T Yagi; K Obata Journal: Proc Natl Acad Sci U S A Date: 1997-06-10 Impact factor: 11.205
Authors: Takanori Hashimoto; Sarah E Bergen; Quyen L Nguyen; Baoji Xu; Lisa M Monteggia; Joseph N Pierri; Zhuoxin Sun; Allan R Sampson; David A Lewis Journal: J Neurosci Date: 2005-01-12 Impact factor: 6.167
Authors: Takanori Hashimoto; David W Volk; Stephen M Eggan; Karoly Mirnics; Joseph N Pierri; Zhuoxin Sun; Allan R Sampson; David A Lewis Journal: J Neurosci Date: 2003-07-16 Impact factor: 6.167
Authors: Marc W Howard; Daniel S Rizzuto; Jeremy B Caplan; Joseph R Madsen; John Lisman; Richard Aschenbrenner-Scheibe; Andreas Schulze-Bonhage; Michael J Kahana Journal: Cereb Cortex Date: 2003-12 Impact factor: 5.357
Authors: Allison A Curley; Stephen M Eggan; Matt S Lazarus; Z Josh Huang; David W Volk; David A Lewis Journal: Neurobiol Dis Date: 2012-10-26 Impact factor: 5.996
Authors: T K Alshammari; M A Alshammari; M N Nenov; E Hoxha; M Cambiaghi; A Marcinno; T F James; P Singh; D Labate; J Li; H Y Meltzer; B Sacchetti; F Tempia; F Laezza Journal: Transl Psychiatry Date: 2016-05-10 Impact factor: 6.222
Authors: Rochelle M Hines; Dustin J Hines; Catriona M Houston; Jayanta Mukherjee; Philip G Haydon; Verena Tretter; Trevor G Smart; Stephen J Moss Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205